



US009533053B2

(12) **United States Patent**  
**Gamache et al.**

(10) **Patent No.:** **US 9,533,053 B2**  
(45) **Date of Patent:** **\*Jan. 3, 2017**

(54) **HIGH CONCENTRATION OLOPATADINE  
OPHTHALMIC COMPOSITION**

USPC ..... 514/449, 450, 777, 778  
See application file for complete search history.

(71) Applicant: **Alcon Research, Ltd.**, Fort Worth, TX  
(US)

(56) **References Cited**

(72) Inventors: **Daniel A. Gamache**, Arlington, TX  
(US); **Laman Alani**, Fort Worth, TX  
(US); **Malay Ghosh**, Fort Worth, TX  
(US); **Francisco Javier Galan**, Teia  
(ES); **Nuria Carreras Perdiguier**,  
Barcelona (ES); **Onkar N. Singh**,  
Arlington, TX (US)

U.S. PATENT DOCUMENTS

- 3,767,788 A 10/1973 Rankin
- 3,843,782 A 10/1974 Krezanoski et al.
- 3,856,919 A 12/1974 Rankin
- 3,931,319 A 1/1976 Green et al.
- 3,947,573 A 3/1976 Rankin
- 4,027,020 A 5/1977 Green et al.
- 4,120,949 A 10/1978 Bapatla et al.
- 4,283,393 A 8/1981 Field et al.
- 4,407,791 A 10/1983 Stark
- 4,470,965 A 9/1984 Wolf et al.
- 4,525,346 A 6/1985 Stark
- 4,836,986 A 6/1989 Ogunbiyi et al.
- 4,871,865 A 10/1989 Lever, Jr. et al.
- 4,923,693 A 5/1990 Michalos
- 5,037,647 A 8/1991 Chowhan et al.
- 5,068,225 A 11/1991 Pennell et al.
- 5,116,863 A 5/1992 Oshima et al.
- 5,134,127 A 7/1992 Stella et al.
- 5,141,961 A 8/1992 Coapman
- 5,300,287 A 4/1994 Park
- 5,342,620 A 8/1994 Chowhan
- 5,376,645 A 12/1994 Stella et al.
- 5,472,954 A 12/1995 Loftsson
- 5,591,426 A 1/1997 Dabrowski et al.
- 5,597,559 A 1/1997 Olejnik et al.
- 5,624,962 A 4/1997 Takeuchi et al.
- 5,641,805 A 6/1997 Hayakawa et al.

(73) Assignee: **Alcon Research, Ltd.**, Fort Worth, TX  
(US)

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 117 days.  
  
This patent is subject to a terminal dis-  
claimer.

(Continued)

(21) Appl. No.: **14/304,124**

(22) Filed: **Jun. 13, 2014**

(65) **Prior Publication Data**

US 2014/0296328 A1 Oct. 2, 2014

**Related U.S. Application Data**

(63) Continuation of application No. 13/475,607, filed on  
May 18, 2012, now Pat. No. 8,791,154.

(60) Provisional application No. 61/548,957, filed on Oct.  
19, 2011, provisional application No. 61/487,789,  
filed on May 19, 2011.

FOREIGN PATENT DOCUMENTS

CA 2 391 076 5/2001  
EP 0214779 B1 3/1987

(Continued)

(51) **Int. Cl.**

- A61K 31/335** (2006.01)
- A01N 43/02** (2006.01)
- A61K 47/00** (2006.01)
- A61K 47/40** (2006.01)
- A61K 9/00** (2006.01)
- A61K 47/32** (2006.01)
- A61K 9/08** (2006.01)
- A61K 47/48** (2006.01)
- C08B 37/16** (2006.01)
- C08L 5/16** (2006.01)
- A61K 47/10** (2006.01)
- B82Y 5/00** (2011.01)

OTHER PUBLICATIONS

James I. McGill, "A review of the use of olopatadine in allergic  
conjunctivitis", 2004, International Ophthalmology, 25(3):171-  
179.\*

(Continued)

(52) **U.S. Cl.**

CPC ..... **A61K 47/40** (2013.01); **A61K 9/0048**  
(2013.01); **A61K 9/08** (2013.01); **A61K 31/335**  
(2013.01); **A61K 47/10** (2013.01); **A61K 47/32**  
(2013.01); **A61K 47/48969** (2013.01); **B82Y**  
**5/00** (2013.01); **C08B 37/0015** (2013.01);  
**C08L 5/16** (2013.01)

*Primary Examiner* — My-Chau T Tran

(74) *Attorney, Agent, or Firm* — Scott A. Chapple

(57) **ABSTRACT**

The present invention is an ophthalmic composition con-  
taining a relatively high concentration of olopatadine. The  
composition is typically an ophthalmic aqueous solution  
containing relatively high concentrations of olopatadine  
solubilized within the solution. The composition is prefer-  
ably capable of providing enhanced relief from symptoms of  
ocular allergic conjunctivitis, particularly late phase symp-  
toms of ocular allergic conjunctivitis.

(58) **Field of Classification Search**

CPC ..... A61K 47/40; A61K 47/10; A61K 9/08;  
A61K 47/48969; A61K 47/32; A61K

(56)

References Cited

U.S. PATENT DOCUMENTS

5,874,418 A 2/1999 Stella et al.  
 5,888,493 A 3/1999 Sawaya  
 5,985,310 A 11/1999 Castillo et al.  
 6,153,746 A 11/2000 Shah et al.  
 6,280,745 B1 8/2001 Flore et al.  
 6,316,483 B1 11/2001 Haslwanger et al.  
 6,407,079 B1 6/2002 Muller et al.  
 6,511,949 B1 1/2003 Nitta et al.  
 6,828,356 B2 12/2004 Su et al.  
 6,995,186 B2 2/2006 Castillo et al.  
 7,074,424 B2 7/2006 Avila et al.  
 7,147,844 B2 12/2006 Hamano et al.  
 7,402,609 B2 7/2008 Castillo et al.  
 7,429,602 B2 9/2008 Trach et al.  
 7,635,773 B2 12/2009 Antle  
 7,687,646 B2 3/2010 Bader et al.  
 7,977,376 B2 7/2011 Singh et al.  
 8,071,073 B2\* 12/2011 Dang ..... A61K 9/0043  
 424/45  
 8,399,508 B2 3/2013 Singh et al.  
 8,791,154 B2\* 7/2014 Gamache ..... A61K 9/0048  
 514/449  
 2002/0006443 A1 1/2002 Curatolo et al.  
 2002/0107238 A1\* 8/2002 Bandyopadhyay ..... B82Y 5/00  
 514/211.15  
 2002/0150616 A1 10/2002 Vandecruys  
 2003/0055102 A1 3/2003 Castillo et al.  
 2003/0170309 A1 9/2003 Babcock et al.  
 2004/0198828 A1 10/2004 Abelson et al.  
 2005/0004074 A1 1/2005 Lyons et al.  
 2005/0191270 A1 9/2005 Gruening et al.  
 2005/0239745 A1 10/2005 Abelson et al.  
 2005/0244472 A1 11/2005 Hughes et al.  
 2006/0210645 A1 9/2006 Du Mee et al.  
 2007/0020336 A1 1/2007 Loftsson et al.  
 2008/0132444 A1 6/2008 Li et al.  
 2008/0139531 A1 6/2008 Yanni et al.  
 2009/0118262 A1 5/2009 Rohrs et al.  
 2009/0136598 A1 5/2009 Chapin et al.  
 2009/0156568 A1 6/2009 Hughes et al.  
 2009/0232763 A1 9/2009 Kabra et al.  
 2009/0239842 A1 9/2009 Trach et al.  
 2010/0010082 A1 1/2010 Chong et al.  
 2010/0240625 A1 9/2010 Abelson et al.  
 2010/0249062 A1 9/2010 Matsumura et al.  
 2010/0324031 A1 12/2010 Kabra  
 2011/0082145 A1 4/2011 Schneider et al.  
 2012/0015953 A1 1/2012 Beauregard et al.

FOREIGN PATENT DOCUMENTS

EP 0235796 B2 9/1987  
 EP 0799044 B1 10/1997  
 EP 1 004 309 5/2000  
 EP 0862414 12/2001  
 EP 0998304 8/2003  
 EP 1 231 920 2/2007  
 EP 1 994 931 11/2008  
 GB 2169508 7/1986  
 JP 2001-158750 6/2001  
 JP 2003520813 7/2003  
 WO 88/08709 11/1988  
 WO 90/04971 5/1990  
 WO 91/09523 7/1991  
 WO 96/39147 12/1996  
 WO 9918963 4/1999  
 WO 0078396 A2 12/2000  
 WO 01/54687 8/2001  
 WO 0224116 A1 3/2002  
 WO 03/013481 2/2003  
 WO 2004024126 A1 3/2004  
 WO 2006/011044 2/2006

WO 2010/107689 9/2010  
 WO 2011138801 A1 11/2011  
 WO 2012159064 11/2012

OTHER PUBLICATIONS

International Preliminary Report on Patentability for corresponding PCT/US2012/038663 with mailing date Nov. 28, 2013.  
 Chigbu, "The management of allergic eye disease in primary eye care", Contact Lens & Anterior Eye, 32, pp. 260-272, 2009.  
 Chigbu, "The pathophysiology of ocular allergy: A review", Contact Lens & Anterior Eye, 32, pp. 3-15, 2009.  
 Ciprandi et al., "Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge", J Allergy Clin Immunol, vol. 95, No. 2, pp. 612-621, Feb. 1995.  
 Du Buske, "Clinical comparison of histamine H1-receptor antagonist drugs", J Allergy Clin Immunol, vol. 98, No. 6, part 3, pp. S307-S318, Dec. 1996.  
 Fukuda et al., "Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis", J Allergy Clin Immunol, vol. 124, No. 4, 827-833.e2, Oct. 2009.  
 International Search Report for corresponding PCT/US2012/038663 with mailing date Jul. 25, 2012.  
 International Written Opinion for corresponding PCT/US2012/038663 with mailing date Jul. 25, 2012.  
 Izushi et al., "The role of histamine H1 receptors in late-phase reaction of allergic conjunctivitis", European Journal of Pharmacology, 440:79-82, 2002.  
 Leonardi and Abelson, "Double-Masked, Randomized, Placebo-Controlled Clinical Study of the Mast Cell-Stabilizing Effects of Treatment with Olopatadine in the Conjunctival Allergen Challenge Model in Humans", Clinical Therapeutics, vol. 25, No. 10, pp. 2539-2552, 2003.  
 Ozaki et al., "Mast-cell activation augments the late phase reaction in experimental immune-mediated blepharoconjunctivitis", Graefe's Arch Clin Exp Ophthalmol, 241:394-402, 2003.  
 Ueta et al., letter to editor, "Development of eosinophilic conjunctival inflammation at late-phase reaction in mast cell-deficient deficient mice", J Allergy Clin Immunol, pp. 476-478, Aug. 2007.  
 Vogelsson et al., "Preclinical and Clinical Antiallergic Effect of Olopatadine 0.2% Solution 24 Hours after Topical Ocular Administration", Allergy and Asthma Proc., vol. 25, No. 1, pp. 69-75, Jan.-Feb. 2004.  
 Yanni et al., "The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), an Effective Anti-Allergic/Antihistaminic Agent", Journal of Ocular Pharmacology and Therapeutics, vol. 12, No. 4, 1996.  
 Abelson et al., "Combined Analysis of Two Studies Using the Conjunctival Allergen Challenge Model to Evaluate Olopatadine Hydrochloride, a New Ophthalmic Antiallergic Agent With Dual Activity," American Journal of Ophthalmology, vol. 125, No. 6, pp. 797-804.  
 Abelson and Anderson, "Demystifying Dumulcents," Review of Ophthalmology, Nov. 2006, pp. 122-125.  
 Ansel, Howard C., Pharmaceutical Calculations, 13th Ed., Wolters Kluwer, 2010, pp. 82-83.  
 Chaudhari et al., "Solubility enhancement of hydrophobic drugs using synergistically interacting cyclodextrins and cosolvent," Current Science, 1586 vol. 92, No. 11, Jun. 10, 2007; pp. 1586-1591.  
 Choi, et al., "Late-phase reaction in ocular allergy," Current Opinion in Allergy and Clinical Immunology, 2008, vol. 8, pp. 438-444.  
 Gennaro, Alfonso R., Remington: The Science and Practice of Pharmacy, Philadelphia College of Pharmacy and Science, 1995, vol. 1, pp. 613-627.  
 Gennaro, Alfonso R., Remington: The Science and Practice of Pharmacy, Philadelphia College of Pharmacy and Science, 1995, vol. 2, pp. 1563-1576.  
 Harada, A., "Preparation and structures of supramolecules between

(56)

**References Cited**

## OTHER PUBLICATIONS

Jansook et al., "CDs as solubilizers: Effects of excipients and competing drugs," *International Journal of Pharmaceutics*, 379, 2009, pp. 32-40.

Lide, David R., *CRC Handbook of Chemistry and Physics*, CRC Press, 2006, pp. 6-4-6-5.

Loftsson et al., "Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye," *Acta Ophthalmologica Scandinavica*, 2002, pp. 144-150.

Loftsson et al., "The effect of water-soluble polymers on the aqueous solubility and complexing abilities of  $\beta$ -cyclodextrin," *International Journal of Pharmaceutics*, 1998, vol. 163, pp. 115-121.

Loftsson, et al., "Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization," *Journal of Pharmaceutical Sciences*, Oct. 1996, vol. 85, No. 10, pp. 1017-1025.

Nandi et al., "Synergistic Effect of PEG-400 and Cyclodextrin to Enhance Solubility of Progesterone," *AAPS PharmSciTech* 2003; 4 (1), pp. 1-5.

PATANOL® Label, Revised Aug. 2002.

PATADAY® Label, Revised Aug. 2010.

PATANASE® Label, Revised Mar. 2008.

Polyvinylpyrrolidone K 30, [http://www4.mpbio.com/ecom/docs/proddata.nsf/\(webtids2\)/102787](http://www4.mpbio.com/ecom/docs/proddata.nsf/(webtids2)/102787), pp. 1-2.

Proud, et al., "Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen provocation of allergic subjects with allergen," *Mediator generation in ocular allergy*, 1989, vol. 85, No. 5, pp. 896-905.

Sharif, et al., "Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases," *The Journal of Pharmacology and Experimental Therapeutics*, 1996, vol. 278, No. 3, pp. 1252-1261.

Swei, et al., "Viscosity Correlation for Aqueous Polyvinylpyrrolidone (PVP) Solutions," *Journal of Applied Polymer Science*, 2003, vol. 90, pp. 1153-1155.

United States District Court for the District of Delaware, Complaint, *Alcon Research, Ltd. v. Watson Laboratories, Inc. et al.*, Dec. 16, 2015, pp. 1-16.

United States District Court for the District of Delaware, Defendants' Answer, Separate Defenses, and Counterclaims, *Alcon Research, Ltd. v. Watson Laboratories, Inc. et al.*, Feb. 29, 2016, pp. 1-26.

United States Patent and Trademark Office Before the Patent Trial and Appeal Board, Petition for Inter Partes Review, *Argentum Pharmaceuticals LLC v. Alcon Research, Ltd.*, U.S. Pat. No. 8,791,154, Feb. 2, 2016, pp. 1-60.

Wade et al., "Ophthalmic antihistamines and H1-H4 receptors," *Current Opinion in Allergy and Clinical Immunology*, 2012, vol. 12, No. 5, pp. 510-516.

Watson Laboratories, Inc., Notification of Certification for U.S. Pat. No. 8,791,154 Pursuant to § 505(j)(2)(B) (iv) of the Federal Food, Drug, and Cosmetic Act, Nov. 3, 2015, pp. 1-25.

Petition for Inter Partes Review, Against Patent 8,791,154 by Argentum Pharmaceuticals LLC Feb. 2, 2016.

Petition for Inter Partes Review, Against Patent 8,791,154 by Apotex Inc. and Apotex Corp. Aug. 18, 2016.

Inter Partes Review No. 2016-00544. Exhibit 1002: Declaration of Dr. Eming Xia.

Inter Partes Review No. 2016-00544. Exhibit 1003: Declaration of Dr. Leonard Bielory.

Inter Partes Review No. 2016-00544. Exhibit 1024: Curriculum Vitae for Dr. Eming Xia.

Inter Partes Review No. 2016-00544. Exhibit 1025: Curriculum Vitae for Dr. Leonard Bielory.

Inter Partes Review No. 2016-00544. Exhibit 1030: *Alcon Research, Ltd. v. Apotex Inc.*, 687 F.3d 1362 (Fed. Cir. 2012).

Inter Partes Review No. 2016-00544. Exhibit 1031: *Alcon Research, Ltd. v. Apotex Inc.*, 790 F. Supp. 2d 868 (S.D. Ind. 2011).

Inter Partes Review No. 2016-00544. Exhibit 1057: 21.C.F.R. § 349.12.

Inter Partes Review No. 2016-00544. Exhibit 1060: 68 Fed. Reg. 106, 32981-32983.

\* cited by examiner




FIG. 1




FIG. 2

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.